Rescue by radiotherapy and anti-CTLA4/PD-1 after failure of anti-PD-1 therapy in metastatic NSCLC patients: The RECLAIM study

被引：0

作者：

Bahce, I. ^{[1
]}

Schneiders, F. L. ^{[2
]}

Hashemi, S. ^{[1
]}

Veltman, J. ^{[3
]}

Daniels, H. ^{[4
]}

Fransen, M. ^{[4
]}

Radonic, T. ^{[5
]}

Ulas, E. ^{[6
]}

Houda, I.

Barlo, N. ^{[7
]}

Disselhorst, M. ^{[8
]}

van Laren, M. ^{[9
]}

Tiemessen, M. ^{[9
]}

Tarasevych, S. ^{[10
]}

van Haarst, J. M. M. ^{[11
]}

van Tilburg, P. ^{[12
]}

Kunst, P. ^{[13
]}

Moons-Pasic, A. ^{[14
]}

de Gruijl, T. D. ^{[15
]}

Senan, S. ^{[2
]}

机构：

[1] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Pulmonary Dis Dept, Amsterdam, Netherlands

[2] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Radiat Oncol Dept, Amsterdam, Netherlands

[3] Vrije Univ Med Ctr VUmc, Pulmonary Med, Amsterdam UMC, Amsterdam, Netherlands

[4] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Pulmonol Dept, Amsterdam, Netherlands

[5] Vrije Univ Med Ctr VUmc, Pathol, Amsterdam UMC, Amsterdam, Netherlands

[6] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Pulmonol Dept, Amsterdam, Netherlands

[7] Noordwest Ziekenhuisgroep, Pulmonol, Alkmaar, Netherlands

[8] Noordwest Ziekenhuisgroep Alkmaar, Pulmonol Dept, Alkmaar, Netherlands

[9] Dijklander Hosp, Pulmonary Dis Dept, Hoorn, Netherlands

[10] Zaans Med Ctr, Pulmonary Dis Dept, Zaandam, Netherlands

[11] Tergooi Ziekenhuizen, Pulmonol Dept, Hilversum, Netherlands

[12] Tergooi Hosp Iocatie Hilversum, Pulmonary Dis Dept, Hilversum, Netherlands

[13] OLVG Hosp, Pulmonary Dis Dept, Amsterdam, Netherlands

[14] OLVG locat West, Pulmonary Dis Dept, Amsterdam, Netherlands

[15] Vrije Univ Med Ctr VUmc, Amsterdam UMC, Med Oncol Dept, Room CCA2 44, Amsterdam, Netherlands

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.1146

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1020P

引用

页码：S1021 / S1021

页数：1

共 50 条

[1] Sarcoidosis Following Anti-PD-1 and Anti-CTLA-4 Therapy for Metastatic Melanoma
Reddy, Swathi B.
Possick, Jennifer D.
Kluger, Harriet M.
Galan, Anjela
Han, Dale
JOURNAL OF IMMUNOTHERAPY, 2017, 40 (08) : 307 - 311
[2] Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone
Afzal, Muhammad Zubair
Mabaera, Rodwell
Shirai, Keisuke
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
[3] Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC
Samuel, Evangeline
Lie, Gabrielle
Balasubramanian, Adithya
Hiong, Alison
So, Yeojeong
Voskoboynik, Mark
Moore, Maggie
Shackleton, Mark
Haydon, Andrew
John, Tom
Mitchell, Paul L. R.
Markman, Ben
Briggs, Peter
Parakh, Sagun
CLINICAL LUNG CANCER, 2021, 22 (03) : E425 - E430
[4] Safety and Activity of Combined Radiotherapy (RT) and Anti-PD-1 Antibodies (PD-1) in Patients (pts) with Metastatic Melanoma
Liniker, E.
Kong, B.
Menzies, A. M.
Cooper, A.
Ramanujam, S.
Lo, S.
Kefford, R. F.
Fogarty, G. B.
Guminski, A.
Wang, T. W.
Carlino, M. S.
Hong, A.
Long, G. V.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S664 - S664
[5] Defining melanoma patients unresponsive to single agent anti-PD-1 therapy but responsive to combination anti-PD-1+anti-CTLA-4 therapy
Edwards, Jarem J.
da Silva, Ines Pires
Ferguson, Angela
Johansson, Peter
Conway, Jordan
Attrill, Grace
Saw, Robyn P. M.
Thompson, John F.
Menzies, Alexander M.
Palendira, Umaimainthan
Long, Georgina, V
Scolyer, Richard A.
Wilmott, James S.
CANCER RESEARCH, 2020, 80 (16)
[6] Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies
Robert, Caroline
Mateus, Christina
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2014, 198 (02): : 297 - 308
[7] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
Bowyer, S.
Prithviraj, P.
Lorigan, P.
Larkin, J.
McArthur, G.
Atkinson, V.
Millward, M.
Khou, M.
Diem, S.
Ramanujam, S.
Kong, B.
Liniker, E.
Guminski, A.
Parente, P.
Andrews, M. C.
Parakh, S.
Cebon, J.
Long, G. V.
Carlino, M. S.
Klein, O.
BRITISH JOURNAL OF CANCER, 2016, 114 (10) : 1084 - 1089
[8] Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
S Bowyer
P Prithviraj
P Lorigan
J Larkin
G McArthur
V Atkinson
M Millward
M Khou
S Diem
S Ramanujam
B Kong
E Liniker
A Guminski
P Parente
M C Andrews
S Parakh
J Cebon
G V Long
M S Carlino
O Klein
British Journal of Cancer, 2016, 114 : 1084 - 1089
[9] Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Gide, Tuba N.
Quek, Camelia
Menzies, Alexander M.
Tasker, Annie T.
Shang, Ping
Holst, Jeff
Madore, Jason
Lim, Su Yin
Velickovic, Rebecca
Wongchenko, Matthew
Yan, Yibing
Lo, Serigne
Carlino, Matteo S.
Guminski, Alexander
Saw, Robyn P. M.
Pang, Angel
McGuire, Helen M.
Palendira, Umaimainthan
Thompson, John F.
Rizos, Helen
da Silva, Ines Pires
Batten, Marcel
Scolyer, Richard A.
Long, Georgina V.
Wilmott, James S.
CANCER CELL, 2019, 35 (02) : 238 - +
[10] Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
Liniker, E.
Menzies, A. M.
Kong, B. Y.
Cooper, A.
Ramanujam, S.
Lo, S.
Kefford, R. F.
Fogarty, G. B.
Guminski, A.
Wang, T. W.
Carlino, M. S.
Hong, A.
Long, G. V.
ONCOIMMUNOLOGY, 2016, 5 (09):

← 1 2 3 4 5 →